Completed PHASE3 INTERVENTIONAL 4-arm NCT00002548

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study

Sponsor: Cancer and Leukemia Group B

Conditions Multiple Myeloma

Interventions allogeneic bone marrow transplantation autologous bone marrow transplantation carmustine cyclophosphamide dexamethasone doxorubicin hydrochloride melphalan peripheral blood stem cell transplantation prednisone radiation therapy recombinant interferon alfa vincristine sulfate

Updated 8 times since 2017 Last updated: Mar 5, 2015 Started: Jan 31, 1994 Primary completion: Oct 31, 2003 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Cancer and Leukemia Group B and has accumulated 8 data snapshots since 1994. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Boston, United States , Chicago, United States , Cleveland, United States , Danville, United States , Denver, United States , Des Moines, United States , Duluth, United States , Evanston, United States and 17 more locations